Trial
NCT01773889
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
—
Condition
Epithelial Ovarian Cancer
Intervention
Denileukin Diftitox/SC Pegylated IFNα-2a
Why stopped
Lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-10